ZYME

#1967
Zymeworks Inc.
27.1571 USD
+3.77%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
27.1500
27.1900
Rango anual
16.0034
28.4900
Cambio diario
+3.77%
Variación mensual
+17.21%
Variación en los últimos 6 meses
+53.08%
Cambio anual
+53.08%
Cierres anteriores
26.1700
Abrir
27.1500
Bid
Ask
Mínimo
27.1500
High
27.1900
Volumen
4
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 2.0028 B
  • Employee 264
  • Founded 2003
  • CEO Kenneth Galbraith
  • Website www.zymeworks.com
  • Headquarter Delaware, United States
  • FIGI BBG019XSYC89
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-24.38
Relación precio/flujo de caja
18.74

Zymeworks Inc

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.

Noticias